Alp, CaglarDogru, Mehmet TolgaKaradeniz, MuhammedSarak, TanerDemir, VahitCelik, YunusKisa, Ucler2020-06-252020-06-252019Alp Ç, Dogru MT, Karadeniz M, Sarak T, Demir V, Çelik Y, Kandemir H, Kısa Ü. Serum pentraxin-3 levels and flow-mediated dilation in dipper and non-dipper hypertension. J Clin Lab Anal. 2019 Mar;33(3):e22718.0887-80131098-2825https://doi.org/10.1002/jcla.22718https://hdl.handle.net/20.500.12587/7839Demir, Vahit/0000-0001-8349-6651; KISA, Ucler/0000-0002-8131-6810; Alp, Caglar/0000-0001-5984-1857Background Endothelial dysfunction is one of the main pathological processes of hypertension. The association of serum pentraxin-3 (PTX3) levels and endothelial dysfunction becomes a more interesting scientific research issue due to high potential of PTX3 as a diagnostic and prognostic biomarker. We aimed to investigate the relationship between serum PTX3 levels and flow-mediated dilation results in patients with dipper and non-dipper hypertension. Methods This study included 90 hypertensive patients were divided into two groups based on 24 hours ambulatory blood pressure monitoring (ABPM): 38 patients with a dipper pattern and 52 patients with non-dipper pattern. Noninvasive evaluation of the endothelial functions was performed using flow-mediated dilation (FMD) method. Results Serum pentraxin-3 levels were higher in patients with non-dipper HT compared to dipper hypertension (P = 0.028). In addition, we found negative correlation between serum PTX3 and FMD basal/FMD hyperemia ratio (r = -0.297, P = 0.05 for FMD basal/FMD hyperemia ratio, respectively). Conclusions Serum PTX3 levels are closely related with the measures of indirect noninvasive evaluation methods (FMD) in both DH and NDH patients.eninfo:eu-repo/semantics/openAccessambulatory blood pressure monitoringdipper hypertensionflow-mediated dilationnon-dipper hypertensionpentraxin-3Article33310.1002/jcla.227182-s2.0-8505631075730411809Q1WOS:000461886300017Q3